Podcast: The Colorful Landscape Of Therapeutic Psychedelics

Datamonitor Healthcare analysts and podcast co-hosts Flora Mackay and Emma Wille discuss the complicated development of therapeutic psychedelics. They dwell on FDA involvement and advisory committees, alongside adverse event reporting and ethical concerns.  

In Vivo Podcast
• Source: Shutterstock

An industry with great demand and seemingly stagnated development, no approvals have been granted within the Post Traumatic Stress Disorder (PTSD) space for 25 years. Current statistics indicate that 4% of the population deal with PTSD worldwide, and this average is greater for those in the US at 7%. For PTSD the FDA has currently approved two SSRI’s including sertraline and paroxetine. 

Looking at the world of psychedelics, the use of MDMA was both considered and tested as a potential new PTSD...

More from Market Intelligence

More from In Vivo